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Oncogenic osteomalacia secondary to  
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Summary
Oncogenic osteomalacia secondary to glomus tumor is extremely rare. Localization of causative tumors is critical as 
surgical resection can lead to a complete biochemical and clinical cure. We present a case of oncogenic osteomalacia 
treated with resection of glomus tumor. A 39-year-old woman with a history of chronic sinusitis presented with chronic 
body ache and muscle weakness. Biochemical evaluation revealed elevated alkaline phosphatase hypophosphatemia, 
increased urinary phosphate excretion, low calcitriol, and FGF23 was unsuppressed suggestive of oncogenic osteomalacia. 
Diagnostic studies showed increase uptake in multiple bones. Localization with MRI of paranasal sinuses revealed a 
sinonasal mass with concurrent uptake in the same area on the octreotide scan. Surgical resection of the sinonasal 
mass was consistent with the glomus tumor. The patient improved both clinically and biochemically postoperatively. 
Along with the case of oncogenic osteomalacia secondary to a glomus tumor, we have also discussed in detail the recent 
development in the diagnosis and management of oncogenic osteomalacia.
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 • Tumor-induced osteomalacia is a rare cause of osteomalacia caused by the secretion of FGF23 from  
mesenchymal tumors.
 • MesenchymaltumorscausingTIOareoftendifficulttolocalizeandtreat.
 • Resection of the tumor can result in complete resolution of biochemical and clinical manifestations in a very short 
span of time.
 • Glomus tumor can lead to tumor induced osteomalacia and should be surgically treated.
Background
Tumor-induced osteomalacia (TIO), also known 
as oncogenic osteomalacia, is a rare and acquired 
paraneoplastic syndrome. TIO is characterized by 
hypophosphatemia, increased urinary phosphate 
excretion and low calcitriol levels due to FGF23, 
secreted by the tumor (1). This ultimately results in 
hypophosphatemic osteomalacia and can have variable 
manifestations ranging from diffuse musculoskeletal 
pain to bone fractures. Despite obvious diagnosis among 
patients presenting with aforementioned clinical and 
biochemical findings, the subsequent localization 
of mesenchymal tumor often remains challenging. 
This results in a significant delay in the diagnosis and 
treatment of these patients. Herein, we are presenting a 
case of TIO caused by glomus tumor localized in the right 
sinus cavity.
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Case presentation
A 39-year-old woman with a past medical history of 
chronic sinusitis presented with progressively worsening 
generalized body pain and muscle weakness of 8 months 
duration. Patient was afebrile and hemodynamically 
stable on presentation. On musculoskeletal examination, 
she had decreased muscle strength in bilateral upper and 
lower extremities. Rest of the physical examination was 
unremarkable except for the presence of a congenital cleft 
palate.
Investigation
Laboratory workup revealed elevated alkaline phosphatase 
603 U/L (44–147 U/L), low serum phosphate 1.5 mg/
dL (3.5–5.0 mg/dL), normal serum calcium 8.9 mg/dL 
(8.3–10.4 mg/dL), normal 25-hydroxyvitamin D 32 ng/dL 
(30–100 ng/dL), elevated 1,25-dihydroxyvitamin D 62 g/
mL (20–45 pg/mL), elevated intact PTH level 99.01 pg/mL 
(8–74 pg/mL), high normal 24 h urinary phosphate levels 
1100 mg/dL, and elevated FGF23 level 128 RU/mL (<108 
RU/mL). Complete blood count was within normal range. 
This is summarized in Table 1. Bone densitometry revealed 
a normal bone density and parathyroid scintigraphy was 
negative for adenoma. Considering clinical symptoms 
along with biochemical evidence of phosphate wasting 
as confirmed by low TRP and an unsuppressed FGF23 
levels, a decision to consider oncogenic osteomalacia as 
an underlying cause for patients’ symptoms was pursued. 
Whole-body bone scan demonstrated an increased 
radiotracer uptake in the elbows, spine, sacroiliac 
joints, knees, ankles and multiple ribs suggestive of an 
inflammatory process. MRI of paranasal sinuses revealed 
a large soft tissue mass completely occupying the right 
frontal, ethmoid, maxillary and sphenoid sinuses and 
expanding into the right nasal cavity suggestive of 
sinonasal polyposis (Fig. 1). 99mTc-Octreotide scan showed 
an abnormal area of increased uptake in the nasopharynx.
Treatment
The sinonasal mass was resected and immune histochemical 
studies showed positive S100 and negative CD34, CK, SMA, 
LCA, SAL4 and Caldesmin suggestive for glomus tumor. 
Ki67 index was 3–4%.
Outcome and follow-up
Postoperatively, phosphate levels normalized to 3 mg/
dL on day 7. At 3 months follow-up visit, FGF23 was 10 
RU/mL, PTH was 40 pg/mL, total calcium was 8.9 mg/dL, 
phosphate was 3.4 mg/dL, and 25-hydroxyvitamin D 32 
ng/mL, which were all within normal limits.
Discussion
Oncogenic osteomalacia, also known as 'tumor-induced 
osteomalacia (TIO)' is a paraneoplastic syndrome resulting 
in biochemical and pathological changes similar to 
hypophosphatemic rickets (1). Glomus tumor as a cause 
of tumor-induced osteomalacia is an extremely rare entity 
with only a limited number of published case reports. 
Table 1 Laboratory results.
Laboratory test Level Reference range
Plasma glucose 104 mg/dL 74–90 mg/dL
Serum calcium, total 8.9 mg/dL 8.3–10.4 mg/dL
Serum phosphate 1.5 mg/dL or 0.97 mEq/L 3.5–5.0 mg/dL
Serum albumin 4.2 mg/dL 3.4–5.4 mg/dL
Blood urea nitrogen 10 mg/dL 6–24 ng/dL
Serum creatinine 0.9 mg/dL 0.60–1.10 mg/dL
Serum aspartate transaminases 23 U/L 8–48 U/L
Serum alanine transaminases 27 U/L 7–45 U/L
Serum alkaline phosphatase 603 IU/L 44–147 IU/L
Intact parathyroid hormone 99.01 pg/mL 8.0–74.0 pg/mL
25-hydroxy vitamin D 32 ng/mL 20–80 ng/mL
1,25-dihydroxy vitamin D 62 pg/mL 20–45 pg/mL
Phosphate in 24 h urine (concentration mg/dL or mEq/L) 1100 mg/day (88 mg/dl or 56.77 mEq/L) 360–1600 mg/day
Creatinine in 24 h urine (concentration mg/dL) 614 mg/day (49.1 mg/dL) 500–200 mg/day
24 h urine calcium (concentration mg/dL) 165 mg/day (13.2 mg/dL) 100–250 mg/day
Urine volume 1250 mL (12.5 dL)
Post-operative phosphate 2.8 mg/dL 3.5–5.0 mg/dL
FGF23 128 RU/mL <or = 108RU/mL




It is a mesenchymal tumor composed of modified smooth 
muscle cells arising from the glomus body, a specialized 
arteriovenous anastomosis that regulates heat in the 
skin. Glomus tumor is predominantly cutaneous, most 
commonly in the subungual region of the finger but can 
occur anywhere in the body, however, they are usually 
benign with very rare malignant variability (2).
The mesenchymal tumors secrete fibroblast growth 
factor 23 (FGF23). Excess FGF23 acts via FGF receptor 
1 (FGFR1) on the kidneys and results in the decreased 
reabsorption of phosphate and decreased production 
of 1,25-dihydroxy vitamin D ultimately resulting in 
hypophosphatemia (3). This results in the biochemical 
finding of hypophosphatemia, low 1,25-dihydroxy vitamin 
D and increased urinary phosphate excretion along with 
the clinical symptoms of osteomalacia characterized by 
bone and muscle pain, muscle weakness, and fractures (4). 
In the majority of cases of oncogenic osteomalacia, FGF23 
is high but it can also be inappropriate in the normal 
range (5). In our patient, FGF23 was inappropriately high, 
in the presence of concomitant hypophosphatemia and 
increased urinary phosphate excretion which led us to 
consider oncogenic osteomalacia as an underlying cause. 
As simultaneous plasma and urine values are more accurate 
when assessing fractional excretion of any molecule, 
particularly ones that can vary throughout the day, TmP/
GFR could not be successfully calculated in our case as we 
only had 24 h urine phosphate and creatinine values but not 
spot urine data. Nevertheless, a successful surgical outcome 
as suggested by rapid resolution of clinical symptoms, 
increase in phosphate level and drop in FGF23 levels after 
surgery retrospectively supports oncogenic osteomalacia 
as the underlying cause in our patient. Typically, these 
patients have normal PTH and calcium levels, however, 
with prolonged disease and treatment, they can develop 
secondary hyperparathyroidism resulting in elevated PTH 
levels (6).
Once the diagnosis is established, detection and 
localization of the causative tumor are the most important 
next step. As these mesenchymal tumors tend to be small in 
size, have an indolent course and are mysteriously hidden 
in unusual places, these are often difficult to localize on 
conventional imaging modalities (7). Imaging modalities 
involving whole-body MRI, 18F-FDG-PET/CT, octreotide 
scan, and 68Ga-DOTATATE PET/CT have been successfully 
used to localize these tumors. One study compared 18F-
FDG PET/CT and 68Ga DOTATATE PET/CT and suggested 
68Ga DOTATATE PET/CT be superior to 18F-FDG PET/
CT in diagnosing TIO and recommended to consider 
68Ga DOTATATE PET/CT as an initial diagnostic test for 
localization studies (8, 9). Despite these approaches, the 
success rates of tumor identification remain to be 65–80%. 
Furthermore, due to this difficulty in tumor detection, 
there is often a significant delay between symptom onset 
and treatment of TIO (10).
Following localization of the tumor, the choice of 
treatment is the surgical resection of the tumor with a 
clear surgical margin to prevent tumor recurrence. FGF23 
has a short half-life of approximately 45 min and hence 
surgical cure can be determined by a drop in FGF23 level 
postoperatively (11). Serum phosphate levels normalize 
between 5 and 10 post-operative days and the majority of 
patients feel better within days to weeks of tumor removal 
resulting in rapid and complete biochemical and clinical 
cures (7). Although the bone starts to heal immediately, it 
may vary depending on the severity of the disease process 
and may take years for significant recovery. Although late 
recurrence has been reported, it is extremely rare and can 
be seen with malignant mesenchymal tumors (12, 13).
When the tumor cannot be localized or is not 
surgically resectable, medical therapy is considered. 
Historically, phosphate and vitamin D supplementation 
used to be the main stay of treatment, however, recently 
Burosumab has become the preferred form of therapy and 
based on ongoing open-label Phase 2 study, it was FDA 
approved in June 2020 for use among patients with TIO. 
It has been shown to improve bone turnover markers and 
parameters of osteomalacia on bone biopsy. Furthermore, 
Figure 1
MRI of paranasal sinus revealed a large soft tissue mass completely 
occupying the right frontal, ethmoid, maxillary and sphenoid sinuses and 
expanding in to the right nasal cavity and deviating nasal septum towards 
the left side.
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it also improves ambulation, reduces pain and results 
in sustained normalization of phosphate levels among 
treated patients (14). The goal of treatment among these 
patients with Burosumab or with phosphate and vitamin 
D supplementation is to achieve a serum phosphate in the 
lower end of the age-appropriate normal range.
Declaration of interest
The authors declare that there is no conflict of interest that could be
perceived as prejudicing the impartiality of the research reported.
Funding
Funding for this case report was provided by the Education Department of 
Pikeville Medical Center, Pikeville, KY.
Patient consent
Written informed consent was obtained from the patient for the publication 
of submitted article.
Author contribution statement
S H, M D, M K, K V, M H D, I N, M N, M A, B H were directly involved in patient 
care and management. M K and R R were directly involved in writing the 
manuscript and literature reviews. K A helped with the diagnosis and 
treatment of the patient as well as edited the manuscript.
References
 1 Minisola S, Peacock M, Fukumoto S, Cipriani C, Pepe J, Tella SH & 
Collins MT. Tumour-induced osteomalacia. Nature Reviews: Disease 
Primers 2017 3 17044. (https://doi.org/10.1038/nrdp.2017.44)
 2 Liapi-Avgeri G, Karabela-Bouropoulou V & Agnanti N. Glomus tumor. 
A histological, histochemical and immunohistochemical study of the 
various types. Pathology, Research and Practice 1994 190 2–10. (https://
doi.org/10.1016/S0344-0338(11)80490-5)
 3 Martin A, David V & Quarles LD. Regulation and function of the 
FGF23/klotho endocrine pathways. Physiological Reviews 2012 92 
131–155. (https://doi.org/10.1152/physrev.00002.2011)
 4 Jonsson KB, Zahradnik R, Larsson T, White KE, Sugimoto T, Imanishi Y, 
Yamamoto T, Hampson G, Koshiyama H, Ljunggren O, et al. 
Fibroblast growth factor 23 in oncogenic osteomalacia and X-linked 
hypophosphatemia. New England Journal of Medicine 2003 348 
1656–1663. (https://doi.org/10.1056/NEJMoa020881)
 5 Florenzano P, Gafni RI & Collins MT. Tumor-induced osteomalacia. 
Bone Reports 2017 7 90–97. (https://doi.org/10.1016/j.bonr.2017.09.002)
 6 Farrow EG & White KE. Tumor-induced osteomalacia. Expert Review 
of Endocrinology and Metabolism 2009 4 435–442. (https://doi.
org/10.1586/eem.09.27)
 7 Chong WH, Molinolo AA, Chen CC & Collins MT. Tumor-induced 
osteomalacia. Endocrine-Related Cancer 2011 18 R53–R77. (https://doi.
org/10.1530/ERC-11-0006)
 8 Agrawal K, Bhadada S, Mittal BR, Shukla J, Sood A, Bhattacharya A 
& Bhansali A. Comparison of 18F-FDG and 68Ga DOTATATE PET/
CT in localization of tumor causing oncogenic osteomalacia. 
Clinical Nuclear Medicine 2015 40 e6–e10. (https://doi.org/10.1097/
RLU.0000000000000460)
 9 El-Maouche D, Sadowski SM, Papadakis GZ, Guthrie L, Cottle-
Delisle C, Merkel R, Millo C, Chen CC, Kebebew E & Collins MT. 
Ga-DOTATATE for tumor localization in tumor-induced osteomalacia. 
Journal of Clinical Endocrinology and Metabolism 2016 101 3575–3581. 
(https://doi.org/10.1210/jc.2016-2052)
 10 Hautmann AH, Hautmann MG, Kölbl O, Herr W & Fleck M. Tumor-
induced osteomalacia: an up-to-date review. Current Rheumatology 
Reports 2015 17 512. (https://doi.org/10.1007/s11926-015-0512-5)
 11 Khosravi A, Cutler CM, Kelly MH, Chang R, Royal RE, Sherry RM, 
Wodajo FM, Fedarko NS & Collins MT. Determination of the 
elimination half-life of fibroblast growth factor-23. Journal of Clinical 
Endocrinology and Metabolism 2007 92 2374–2377. (https://doi.
org/10.1210/jc.2006-2865)
 12 Ogose A, Hotta T, Emura I, Hatano H, Inoue Y, Umezu H & Endo N. 
Recurrent malignant variant of phosphaturic mesenchymal tumor 
with oncogenic osteomalacia. Skeletal Radiology 2001 30 99–103. 
(https://doi.org/10.1007/s002560000306)
 13 Folpe AL, Fanburg-Smith JC, Billings SD, Bisceglia M, Bertoni F, 
Cho JY, Econs MJ, Inwards CY, Jan de Beur SM, Mentzel T, et al. 
Most osteomalacia-associated mesenchymal tumors are a single 
histopathologic entity: an analysis of 32 cases and a comprehensive 
review of the literature. American Journal of Surgical Pathology 2004 28 
1–30. (https://doi.org/10.1097/00000478-200401000-00001)
 14 Imanishi Y, Ito N, Rhee Y, Takeuchi Y, Shin CS, Takahashi Y, 
Onuma H, Kojima M, Kanematsu M, Kanda H, et al. Interim analysis 
of a phase 2 open-label trial assessing Burosumab efficacy and 
safety in patients with tumor-induced osteomalacia. Journal of Bone 
and Mineral Research 2021 36 262–270. (https://doi.org/10.1002/
jbmr.4184)
Received in final form 10 February 2021
Accepted 25 May 2021
